Jungyeon Kim

Cheongju-si, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort.

Analysis of Clinical Characteristics and Treatment Efficacy in the Korean Hepatitis B Cohort.

Journal: Public health weekly report
Published: January 07, 2026

Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study.

Disease burden of chronic hepatitis B and C patients in South Korea: a population-based 16-year cohort study.

Journal: BMC infectious diseases
Published: June 10, 2025

In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2.

In silico screening and experimental validation identify riboflavin as an RNA-targeted antiviral against SARS-CoV-2.

Journal: Scientific reports
Published: May 09, 2025

Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.

Long-term pulmonary sequelae and convalescent immune reactions in mild to moderate COVID-19 patients during the active treatment era.

Journal: PloS one
Published: March 13, 2025

Cytokine and Whole-Genome Sequence Analysis in Korean Patients With Multisystem Inflammatory Syndrome in Children.

Cytokine and Whole-Genome Sequence Analysis in Korean Patients With Multisystem Inflammatory Syndrome in Children.

Journal: Journal of Korean medical science
Published: December 19, 2024

Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study.

Risk of postacute sequelae of COVID-19 and oral antivirals in adults aged over 60 years: A nationwide retrospective cohort study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: October 27, 2024

Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea.

Selected Acute Safety Events Following the Use of Nirmatrelvir/Ritonavir or Molnupiravir for COVID-19: A Nationwide Cohort Study in South Korea.

Journal: Clinical pharmacology and therapeutics
Published: July 23, 2024

Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea.

Nationwide Target Trial Emulation Evaluating the Clinical Effectiveness of Oral Antivirals for COVID-19 in Korea.

Journal: Journal of Korean medical science
Published: May 21, 2024

Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.

Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study.

Journal: Infection & chemotherapy
Published: September 13, 2023

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study.

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study.

Journal: Osong public health and research perspectives
Published: August 16, 2023

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022.

Effectiveness of Paxlovid, an Oral Antiviral Drug, Against the Omicron BA.5 Variant in Korea: Severe Progression and Death Between July and November 2022.

Journal: Journal of Korean medical science
Published: February 14, 2023

Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea.

Clinical outcomes of remdesivir-treated COVID-19 patients in South Korea.

Journal: Osong public health and research perspectives
Published: April 27, 2022
Showing 1-12 of 13

Last Updated: 09/26/2026